Regeneron PharmaceuticalsREGN

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is a fully integrated biotechnology company that discovers, develops, manufactures, and commercializes prescription medicines, chiefly biologics targeting serious diseases. Its commercial portfolio is anchored by Eylea and Eylea HD, injectable therapies for retinal vascular diseases including wet age-related macular degeneration and diabetic macular edema, and by Dupixent, an immunology antibody for atopic dermatitis, asthma, and related type 2 inflammatory conditions that is co-developed and co-commercialized with Sanofi. Additional products include the oncology antibodies Libtayo and Praluent, and Evkeeza for a rare lipid disorder. Product sales generate most revenue, with the Sanofi collaboration providing substantial profit share; Eylea and Dupixent economics together typically drive the bulk of profit.

Investors monitor concentration around a handful of franchises, particularly the trajectory of Eylea in the face of biosimilar entrants and competing long-acting anti-VEGF therapies, and the durability of Dupixent as label expansions continue. The structure of the Sanofi antibody collaboration, which shares profits and losses on Dupixent and Libtayo, is a recurring analytical thread, as is the VelocImmune-based pipeline productivity that underpins internal R&D. Reimbursement dynamics in ophthalmology, U.S. drug-pricing legislation, and Food and Drug Administration decisions on line extensions carry weight. Capital allocation leans toward research reinvestment and share repurchases rather than dividends, and founder-led scientific leadership together with a dual-class governance history shape board oversight.

Regeneron was founded in 1988 by Leonard Schleifer, who remains chief executive, with George Yancopoulos joining shortly afterward as founding scientist and subsequently president and chief scientific officer. The company listed publicly on Nasdaq in 1991 and spent its first years as a clinical-stage neurotrophic-factor researcher before pivoting to antibody and trap technologies. A 2003 collaboration with Sanofi (then Aventis) scaled its antibody pipeline, and the 2011 U.S. approval of Eylea transformed it into a large, profitable commercial enterprise. Dupixent's 2017 approval, developed with Sanofi, was a second inflection. Regeneron operates as a single company headquartered in Tarrytown, New York, with manufacturing in Rensselaer, New York, and Limerick, Ireland.

Customers are principally specialty distributors, wholesalers, hospitals, and retinal physician practices in the United States, who in turn are reimbursed by Medicare Part B, commercial insurers, and Medicaid; ex-U.S., Bayer commercializes Eylea outside the United States and Sanofi books Dupixent sales globally while sharing profits. Contracts run through group purchasing organizations and payer rebate arrangements, with buy-and-bill economics important in ophthalmology. Competitive position rests on validated biologic franchises, the VelocImmune fully human antibody platform, and in-house biologics manufacturing. Principal rivals include Roche and Novartis in ophthalmology and large immunology developers such as AbbVie and Amgen. The United States generates the majority of product revenue, with international exposure arriving mainly through collaboration profit share.

Company profile by LineVest editorial. Journalism, not investment advice. Commission a full SEC-based report on Regeneron Pharmaceuticals →